SCHEMBL4890842

SCHEMBL4890842

COC(=O)COc1ccc(Cn2ccn(Cc3ccc(CP(=O)(OF)OF)c(Br)c3)c2=O)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 2/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
HPGD P15428 2/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
GLA P06280 1/20 0.35
MAPK10 P53779 2/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPK1 P28482 1/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898616 0.90 TDP1 (0.40) TSHRNPC1RAB9ANFKB1NFKB2
SCHEMBL4890840 0.82 PTPN1 (0.38) LMNASMN1; SMN2TSHRGAAHTT
SCHEMBL4901226 0.81 MAPK10 (0.46) SMN1; SMN2GAARAB9AMAPK10ALDH1A1
SCHEMBL4903501 0.78 ALDH1A1 (0.43) SMN1; SMN2GAAMAPK10MAPTALDH1A1
SCHEMBL4894929 0.72 PTPN1 (0.41)
SCHEMBL4898615 0.71 PTPN1 (0.45) TSHRMAPT
SCHEMBL4899408 0.69 HDAC1 (0.42) MAPK10ALDH1A1
SCHEMBL4900439 0.69 HTT (0.36) LMNASMN1; SMN2TSHRGAAHTT
SCHEMBL4895554 0.67 MAPK8 (0.43) SMN1; SMN2MAPK10ALDH1A1KDM4E
SCHEMBL4900023 0.66 MAPK10 (0.40) LMNASMN1; SMN2MAPK10MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS LMNA 3553/4885SMN1; SMN2 2338/4885TSHR 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.